Recce Pharmaceuticals is positioned to gain from a new US$66.9 billion US government strategy focused on combating pandemics, antimicrobial resistance, and biological threats. The plan prioritizes broad-spectrum antimicrobials with US$4.46 billion allocated for developing treatments against drug-resistant infections, aligning closely with Recce's synthetic anti-infective technology. Recce's lead candidate, RECCE® 327, shows activity against key pathogens identified in the strategy, supported by existing US defense collaborations and grants. While the company is optimistic about opportunities from this initiative, it cautions that additional funding is not guaranteed.
Cardano's delegated representatives voted down a $12.29 million funding request for Input Output's Pogun project, designed to integrate Bitcoin into decentralized finance. Although the Constitutional Committee unanimously approved the proposal, the D...
Broadcom has declared its next quarterly dividend of $0.65 per share, payable on September 30, 2026, unchanged from the previous quarter. This marks the company's 16th consecutive year of dividend increases, highlighting its commitment to long-term d...
ZETA holders approved a 1:1 token migration from the ZetaChain blockchain to Solana's SPL token standard with 99.4% support, leading to the shutdown of ZetaChain's own blockchain. The swap date is not yet set, and holders generally do not need to act...
The Fidelity Low Duration Bond Factor ETF (FLDR) provides investors with ultra-short duration, high-quality investment-grade bonds, minimizing interest rate and credit risks. With a duration of 0.9 years and mostly AA/single A rated bonds, it offers ...
The Vanguard International High Dividend Yield ETF (VYMI) is rated Buy due to its strong sector positioning in financials, energy, and healthcare, which supports dividend growth and capital appreciation. It has outperformed peers with a 5-year averag...
